<?xml version="1.0" encoding="UTF-8"?>
<p>A new mRNA vaccine (mRNA-1273) was developed by a clinical stage biotechnology company, named Moderna, Inc., USA, which is a pioneering messenger RNA (mRNA) therapeutics and vaccines firm, has initiated Phase-I clinical trials on March 16, 2020 against SARS-CoV-2. This mRNA vaccine encoding for a prefusion stabilized form of the Spike (S) protein of SARS-CoV-2.
 <sup>
  <xref rid="cit0037" ref-type="bibr">37</xref>
 </sup> The Phase-I study evaluated the safety and immunogenicity of three dose levels of mRNA-1273 (25, 100, and 250 μg) administered on a two-dose vaccination schedule, given 28 days apart in 45 healthy adults enrolled in the study. The phase 3 clinical trial of mRNA-1273 has started in the U.S. Clinical research site enrolling approximately 30,000 adult individuals.
</p>
